https://pubmed.ncbi.nlm.nih.gov/32244252/
Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care....
newly diagnosedal amyloidosisdaratumumabpluscybord